This report highlights the direct spending of the state on various models of providing medication free of charge for people with schizophrenia.
On 1 January 2008, the current scheme came into force where, for the first two years after diagnosis, persons with schizophrenia will receive medication free of charge to treat schizophrenia. This scheme entails an immediate revenue loss of DKK 2.3 million per year (continuous) for the state. The revenue loss is limited to people with a pure schizophrenia diagnosis (F20).
The impact on government spending is further calculated for three different models:
- Delivery of medicines free of charge for 7 years: Provides a continuous direct revenue loss (net) of DKK 5.5 million per year.
- Delivery of medicines free of charge until the 40th year: Provides a continuous direct revenue loss (net) of DKK 9.6 million per year.
- Delivery of medicines free of charge for the rest of your life: Provides a continuous direct revenue loss (net) of DKK 26.3 million per year.
- The report was prepared by Højbjerre Brauer Schultz on behalf of Lundbeck Pharma and Otsuka Pharma Scandinavia AB.
The study is commissioned by Lundbeck Pharma and Otsuka Pharma Scandinavia AB.
Links
Højbjerre Brauer Schultz (2019): "Vederlagsfri medicin til personer med skizofreni".
